AP-SA01 / Armata - LARVOL DELTA

Lytic activity of phages against bacterial pathogens infecting diabetic foot ulcers. (PubMed, Sci Rep) - "Furthermore, AB-SA01 and AB-PA01 treatment significantly (p < 0.05) reduced the biofilm biomass of their hosts, regardless of the antibiotic-resistant characteristics of the isolates and the presence of a non-susceptible host. In conclusion, the strong lytic activity, broad host range, and significant biofilm biomass reduction of AB-SA01 and AB-PA01 suggest the considerable potential of phages in treating antibiotic-resistant S. aureus and P. aeruginosa infections alone or as coinfections in DFUs."

Journal • Diabetes • Infectious Disease • Metabolic Disorders

Bacteriophage AB-SA01 Cocktail in Combination with Antibiotics against MRSA-VISA Strain: In vitro Pharmacokinetic/Pharmacodynamic Model. (PubMed, Antimicrob Agents Chemother) - "In addition, BACs resulted in enhancement in bacterial eradication in SEV models. Our findings support the potential activity of BAC therapy for combating serious methicillin-resistant Staphylococcus aureus (MRSA) infections."

Combination therapy • Journal • PK/PD data • Preclinical • Infectious Disease

Safety of bacteriophage therapy in severe Staphylococcus aureus infection. (PubMed, Nat Microbiol) - "No adverse reactions were reported, and our data indicate that AB-SA01 administered in this way is safe in severe S. aureus infections, including infective endocarditis and septic shock. Future controlled trials will be needed to determine the efficacy of AB-SA01 but no phage resistance evolved in vivo and the measurements of bacterial and phage kinetics in blood samples suggest that 12 h dosing of 10 plaque-forming units may be a rational basis for further studies."

Clinical • Journal • Cardiovascular • Hypotension • Pain • Septic Shock

Efficacy of phage cocktail AB-SA01 therapy in diabetic mouse wound infections caused by multidrug-resistant Staphylococcus aureus. (PubMed, BMC Microbiol) - "Topical application of phage cocktail AB-SA01 is effective, as shown by bacterial load reduction and wound closure, in the treatment of diabetic wound infections caused by MDR S. aureus. Our results suggest that topical phage cocktail treatment may be effective in treating antibiotic-resistant S. aureus DFU infections."

Journal • Preclinical • Diabetes • Metabolic Disorders

Safety and efficacy of bacteriophage therapy: the Australian experience (ECCMID 2019) - "AB-SA01 is safe and well tolerated as an adjunct to antibiotics in patients with severe S. aureus infections. Decrease in Staphylococcal DNA load during BT is reflected in improvement of objective clinical criteria. Bacteriophage titre rapidly decreased after IV administration."

Clinical • Cardiovascular • Immune Modulation • Immunology • Inflammation

Efficacy of Lytic Phage Cocktails on Staphylococcus aureus and Pseudomonas aeruginosa in Mixed-Species Planktonic Cultures and Biofilms. (PubMed, Viruses) - "The in vitro lytic efficacies of phage cocktails AB-SA01, AB-PA01, which target Staphylococcus aureus and Pseudomonas aeruginosa, respectively, and their combination against their hosts were evaluated in S. aureus and P. aeruginosa mixed-species planktonic and biofilm cultures...During real-time monitoring using fluorescence spectrophotometry, the density of mCherry S. aureus KUB7 and GFP P. aeruginosa PAO1 significantly decreased when treated by their respective phage cocktail, a mixture of phage cocktails, and gentamicin...This study result shows that these phage cocktails lyse their hosts in the presence of non-susceptible bacteria. These data support the use of phage cocktails therapy in infections with multiple bacterial species."

Journal • Preclinical • Immunology

Safety and Tolerability of Bacteriophage Therapy for Chronic Rhinosinusitis Due to Staphylococcus aureus. (PubMed, JAMA Otolaryngol Head Neck Surg) - "...To investigate the safety, tolerability, and preliminary efficacy of ascending multiple intranasal doses of investigational phage cocktail AB-SA01 in patients with recalcitrant CRS due to S aureus...Phage therapy could be an alternative to antibiotics for patients with CRS. http://anzctr.org.au identifier: ACTRN12616000002482."

Clinical • Journal

Design and Preclinical Development of a Phage Product for the Treatment of Antibiotic-Resistant Staphylococcus aureus Infections. (PubMed, Viruses) - "In both neutropenic and immunocompetent mouse models of acute pneumonia, AB-SA01 reduced lung S. aureus populations equivalently to vancomycin. Overall, the inherent characteristics of AB-SA01 component phages meet regulatory and generally accepted criteria for human use, and the preclinical data presented here have supported production under good manufacturing practices and phase 1 clinical studies with AB-SA01."

Journal • Preclinical